Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial

Hoffmann, Simone; Schrezenmeier, Eva; Desmarets, Maxime; Halleck, Fabian; Dürrbach, Antoine; Peters, Lynn; Tremmel, Anna; Seidel, Alina; Führer, Marita; Bachmann, Friederike; Schrezenmeier, Jens; Greiner, Jochen; Körper, Sixten; Hofmann, Henrike; Ludwig, Carolin; Vieweg, Christiane; Jahrsdörfer, Bernd; Budde, Klemens; Schmidt, Michael; Münch, Jan; Joher, Nizar; Daguindau, Étienne; Grüner, Beate; Brunotte, Gaëlle; Vauchy, Charline; Seifried, Erhard; Bradshaw, Daniel; J Estcourt, Lise; Roberts, David; Toussirot, Éric; Rijnders, Bart; Tiberghien, Pierre; Schrezenmeier, Hubert

doi:10.1016/j.ebiom.2025.105613

Public

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial

Published in EBioMedicine • Feb 27, 2025

Authors:

Simone Hoffmann

Eva Schrezenmeier

Maxime Desmarets

Abstract

BACKGROUND: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19. This study investigated the safety and efficacy of early, very high-titre CCP in immunocompromised individuals with mild COVID-19. METHODS: This randomised, controlled, open-label trial assessed CCP in immunocompromis...

Subject

Convalescent plasma

Coronavirus disease 2019 (COVID-19)

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!